Opinion

Video

Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

Panelists discuss the latest efficacy data from the CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM), the significance of minimal residual disease (MRD) negativity, and how real-world and patient-reported outcomes influence the decision to use chimeric antigen receptor (CAR) T-cell therapy for early-stage R/R MM. They also compare standard-of-care idecabtagene vicleucel (ide-cel) and cilta-cel in this patient population.

Video content above is prompted by the following:

  • Please comment on the latest efficacy data from CARTITUDE-4, evaluating cilta-cel in patients with R/R MM.
  • CARTITUDE-4, MRD negativity
  • How do real-world and/or patient-reported outcomes inform your decision of CAR T for early-stage R/R MM?
  • CARTITUDE-4, patient-reported outcomes
  • Comparison, standard-of-care ide-cel and cilta-cel in R/R MM:
Related Videos
5 experts are featured in this series
5 experts are featured in this series